Blue Water Acquisition III Unit. (BLUWU) vs PharmaCyte Biotech (PMCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLUWU | PMCB |
|---|---|---|
| Share price | $10.42 | $3.98 |
| Market cap | — | $2.25M |
| 1-day change | 0.00% | -12.83% |
| YTD return | -1.23% | — |
| EPS (TTM) | — | $-43.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $4.67M | $-19.42M |
| 52-week high | $12.85 | $28.69 |
| 52-week low | $0.00 | $3.98 |
| Distance from 52-week high | -18.91% | -86.14% |
| Average volume | 45 | 14.79K |
| Shares outstanding | — | 566.09K |
| Employees | — | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Blue Water Acquisition III Unit.
BLUWU stock →Blue Water Acquisition Corp. III does not have significant operations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2 employees
BLUWU vs PMCB FAQ
Are Blue Water Acquisition III Unit. and PharmaCyte Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.